Brought to you by 
Marinus applies Ligand's Captisol to its ganaxolone
10 Apr 2017
Executive Summary
Ligand Pharmaceuticals Inc. granted Marinus Pharmaceuticals Inc. exclusive worldwide rights to use its Captisol drug delivery technology (which Ligand will exclusively supply) to formulate Marinus' intravenous ganaxolone, a synthetic analog of the naturally occurring neuroactive steroid allopregnanolone, and a positive allosteric modulator of the GABA-A receptor, which exhibits both anticonvulsive and antianxiety effects.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com